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Background: Patients with gastrointestinal food allergy are characterised by increased production of mast cell
derived mediators upon allergen contact and present often with unspecific symptoms. The aim of this study was to
evaluate urinary histamine and methylhistamine excretion in patients with food allergy and to compare their values
with food-tolerant controls.
Methods: In a retrospective case control study the urinary excretion parameters were analysed from 56 patients
(40.9, 19 – 58 years) in whom later food challenge tests confirmed food allergy. During their diagnostic work-up
urine was collected during a 12-h period under an unrestricted diet with staple foods and a hypoallergenic
potato-rice-diet (each 2 days). Healthy controls underwent the same diet types to define normal excretion
parameters. Urinary histamine and n-methylhistamine were determined by ELISA or tandem mass spectrometry,
respectively, and were expressed as median (25 – 75% range, μg/mmol creatinine x m2BSA).
Results: During unrestricted diet urinary histamine was significantly higher in gastrointestinal food allergy than
healthy controls (1.42, 0.9 – 2.7 vs 0.87, 0.4 – 1.3; p < 0.0001), while the difference between both groups became
marginal during potato-rice diet (1.30, 0.7 – 2.1 vs 1.05, 0.5 – 1.5; p = 0.02).
N-methylhistamine was found to be significantly elevated in gastrointestinal food allergy both during unrestricted
diet (7.1, 5.0 – 11.2) and potato-rice diet (5.7, 3.7 – 8.7) compared to controls (p < 0.0001). Interestingly, urinary
methylhistamine excretion (p < 0.004) and clinical symptom score (p < 0.02) fell significantly when the diet was
switched from unrestricted to hypoallergenic food, but was not correlated with symptom scores.
Conclusions: In gastrointestinal food allergy significantly higher levels of urine histamine and methylhistamine
excretion were found under unrestricted diet, reflecting an increased secretion of histamine due to offending
foods. Measurement of urinary n-methylhistamine levels may help to find out patients with increased histamine
production and/or food-allergen induced clinical symptoms, respectively.
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Figure 1 A large number of patients with functional adverse
food reactions were identified as carbohydrate malassimilation
with/without small intestinal bowel overgrowth (SIBO), while a
minority had non-allergic food intolerance or Irritable Bowel
Syndrome (IBS). Among the remaining 225 patients an allergic
disease could be excluded definitively, while 153 had strong clinical
suspicion of gastrointestinally mediated allergy (GMA) and were
scheduled for confirmatory food challenge tests. However, only in 56
patients completed diagnostics was obtained and this group with
confirmation of allergy is further described as study group GMA.
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Gastrointestinal complaints after the ingestion of certain
foodstuff can occur in a large variety and can range as
simple symptoms from bloating to severe symptoms like
generalized skin reactions, gastroenteritis, colitis etc up
to complications like bronchospasm and anaphylaxis.
For differential diagnosis various clinical conditions have
to be regarded and specifically examined such as food
hypersensitivity, enzyme deficiencies, irritable bowel syn-
drome (IBS), Inflammatory Bowel Disease, dyspepsia, eo-
sinophilic gastroenteritis and several others. However,
objectification of immunologically mediated food hy-
persensitivity at the gastrointestinal level remains prob-
lematic, since atopy status is not a consistent feature in
gastrointestinally mediated allergy (GMA), skin tests and
allergen specific serum IgE detection may fail to show
clear signs of food-specific sensitisation [1-5] and do not
necessarily indicate symptomatic food allergy. In addition,
allergic reactions of the gastrointestinal tract may follow
either local intestinal IgE- or non-IgE mediated mecha-
nisms or may occur from systemic IgE positive food al-
lergy. Thus, several other functional tests using blood cells
(basophil histamine, or leukotriene release), lymphocyte
transformation tests or measurement of mediators in
blood or serum [6-8] have been proposed to diagnose food
hypersensitivity [3-7]. But only oral food challenge tests,
referred to as the ‘gold standard’ for food allergy diagnosis,
confirms the diagnosis, albeit in adults not all gastrointes-
tinal reactions have been found to be IgE mediated
[1,4,5,7-9].
However, until patients with recurrent gastrointestinal
complaints due to food hypersensitivity undergo double-
blind, placebo-controlled food challenge tests (DBPCFC) a
substantial number of other differential diagnoses is to be
excluded and finally, only a minority of patients under-
went standardized food challenge procedures [1,3,8]. Since
DBPCFC is both time and cost consuming, may put the
patient at a more or less severe risk, allows only one food
to be tested per 1 – 3 days [7,8,10], appropriate selec-
tion of individuals who should undergo challenge tests
would be advisable. Since GMA includes heterogeneous
patient subpopulations urinary histamine (UH) and urin-
ary methylhistamine (UMH) excretion, as possible signs of
manifest allergic disease, were evaluated in conjunction
with clinical symptoms in a cohort of 56 patients with
later confirmed GMA during two days of unrestricted diet
(normal diet containing the usual staple foods) and subse-
quent two days of hypoallergenic potato-rice diet (elimin-
ation diet). The aim of this study was to define normal
excretion rates of UH and UMH in a healthy non-allergic
control group with food tolerance, to assess the rates of
UH and UMH in food allergic individuals and to test
whether one of these parameters might be used as poten-
tial screening parameter for GMA.Methods
Study design and patient recruitment
Among a large number of patients with food related symp-
toms extensive differential diagnostics was performed to
separate patients with various organpathological diseases,
infectious disease and celiac disease from those with func-
tional adverse food reactions.
During the study period (2007 – 2011) 2816 individuals
were identified with functional food reactions (Figure 1).
Following diagnoses were confirmed in these patients,
carbohydrate malassimilation, and/or small intestinal bac-
terial overgrowth, non-allergic intolerances and IBS or
somatoforme diseases, respectively. Patients with prompt
resolution of symptoms after diet or therapy were ex-
cluded from further allergy testing.
In 225 patients (7.9%) food allergy was initially sus-
pected to induce adverse food reactions. Detailed clinical
and diagnostic analysis (see below) did not show any
signs of immunological sensitization or consistent evi-
dence for food-induced symptoms in 72 patients.
The remaining 153 patients (5.4%) were further sub-
jected to below listed diagnostic measures for confirmation
of food allergy by oral food challenge tests, but complete
Figure 2 The control group consisted of 19 healthy volunteers
without any food related symptoms and 25 patients with
non-allergic food intolerance. As indicated for the 20 patients
with carbohydrate malassimilation food allergy was specifically
excluded by clinical diagnostics, skin tests, specific serum IgE and
in unclear cases (n = 6) even with double-blinded, placebo-controlled
food challenges with negative findings.
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confirmation of GMA was later achieved by single- or
double blind food challenge tests (BPCFCs). The main rea-
sons for not completing the whole diagnostic pathway for
confirmation of GMA in the 153 patients were (i) discon-
tinuation before completing diagnostics (n = 14), (ii) non-
compliance with the below listed functional diet test
(n = 17), (iii) violation of the study protocol (n = 11; mostly
alcohol consumption during the test days) or (iv) no
willingness, no time or fear of oral food challenge tests
(n = 111).
Study group gastrointestinally mediated allergy (GMA)
Inclusion criteria for further confirmation of GMA were
(i) food-related symptoms not attributable to another or-
ganic, functional or psychosomatic disease, (ii) persistent
food-related symptoms despite adequate diet in carbohy-
drate malassimilation, (iii) history of atopy, previous
typical signs of allergic disease (e.g. anaphylaxis, asthma
bronchiale, urticaria, skin reactions, etc.), (iv) previous
findings with pathological skin tests or elevated serum
IgE and/or other immunological abnormalities (e.g. eo-
sinophilia, mast cell infiltration etc.).
Exclusion criteria for investigating GMA and further
involvement in the mediator excretion analysis were
(i) another detectable organic disease (e.g. Inflammatory
Bowel Disease), (ii) medication with immunosuppres-
sants, mast cell regulating drugs, antihistamines or
cromoglycate and biologicals (e.g. anti-IgE) or (iii) evi-
dence of an underlying malignant disease, pregnancy, or
chemoradiation.
In 56 patients with the given inclusion and exclusion
criteria full confirmation of GMA was achieved. This
group is classified as GMA (study group) and will later
be compared with a non-allergic control group (Figure 2)
for the excretion of histamine and methylhistamine in
urine.
The clinical characteristics, comorbidity, demographics
and total serum IgE levels of the GMA group are listed
in Table 1 and compared with the control group.
Clinical and allergological standard diagnostics in
patients with gastrointestinally mediated allergy (GMA)
Following tests were done in each GMA patient (100%)
with suspected food allergy to clearly exclude other dis-
eases like infections, celiac disease, colitis, Inflammatory
Bowel Disease, lymphoma, mastocytosis, and many
others: Blood count, serology including transglutaminase
antibodies, serum eosinophilic cationic protein, IgG,
IgA, IgM, IgE, stool cultures, H2 breath tests, transab-
dominal sonography, upper and lower endoscopy and
histology. Additional tests were done in 20 of 56 patients
(35.7%) with determination of faecal elastase 1, in 8 pa-
tients (14.2%) with small bowel capsule endoscopy torule out rare small bowel diseases [10], in 8 patients
(14.2%) with measurement of plasma TNF and immune
complexes to identify non-IgE mediated allergy types
and in 4 patients (7.1%) with bone marrow biopsy.
Every patient was assessed on grounds of their history
and detailed skin prick tests of environmental allergens
(moulds, fibres, bacteria, pollen, dust) and staple food al-
lergens (beef, egg, fish, fruit, pork, wheat, rye, soy, bran,
milk, cheese and nuts). According to patients’ history
some skin tests were extended for barley, coffee, oats,
maize, peach and vegetables. Total and antigen-specific
serum IgE detections were performed for staple foods
and the putative allergens according to the patients’ his-
tory or skin tests. Case history, skin test reactions and
serum antigen-specific IgE testing were supplemented
with determination of intestinal antigen-specific IgE dur-
ing endoscopically guided segmental gut lavage as de-
scribed previously [11] before performing BPCFC. In the
case of uncertainties about non-tolerated foods, tests were
conducted only for staple foods. Patients with pathological
H2 breath tests who developed further food-induced reac-
tions despite strict carbohydrate avoidance, were also con-
sequently suspected of having allergic or non-allergic
hypersensitivity. Therefore, they were further subjected to
above listed allergy diagnostics and later classified as
GMA with associated carbohydrate malassimilation when
immune sensitization signs and BPCFCs were positive.
Table 1 Demographics and clinical characteristics of the study groups with gastrointestinally mediated allergy (GMA)
and the non-allergic control group
Gastrointestinally mediated allergy Non-allergic control group*
n = patients (%) n = patients (%)
Number of patients n = 56 n = 44
Age [years] 40.9 (19–58) 38.2 (16–76)
Sex [female/male] 35/21 20/24
Healthy volunteers 0/56 19/44
Carbohydrate malassimilation 29/56 (57.1) 20/44
Total serum IgE [kU/L] 74 (28–132) 49 (12–122)
Atopy 36/56 5/44
Confirmation of GMA by 56/56 0/56
DBPCFC/SBPCFC 41positive/15positive 6 DBPCFC negative/0
Other comorbidities
Sensitization to grass/tree pollen 14/56 5/44
Associated gastroenterological diagnoses
(esophagitis, ulcer, pancreatitis, colitis)
11/56 3/44
Oral allergy syndrome 5/56 0/44
Atopic dermatitis 5/56 0/44
Allergic rhinitis and/or conjunctivitis 4/56 7/44
Eosinophilic esophagitis 2/56 0/44
Anaphylaxis 2/56 0/44
Asthma bronchiale 1/56 0/44
*The control group consisted of 19 healthy volunteers without any food intolerance and 25 patients with non-allergic carbohydrate malassimilation (n = 20),
exocrine pancreatic insufficiency (n = 3) and psychosomatic disease (n = 2). The group with gastrointestinally mediated allergy (GMA) includes 56 patients, in
whom the allergic disease was proven oral food challenge tests. The different types of allergy found in this group are further differentiated and illustrated
in Table 2.
Atopy status was defined as positive, when history or clinical manifestation of the patient gave evidence for seborrheic dermatitis, atopic dermatitis or eczema,
asthma bronchiale and/or allergic rhino - conjunctivitis.
N = patient number, DBPCFC/SBPCFC double-blinded- or single-blinded, placebo-controlled food challenge test
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diagnostics (given below) [1-4,12]. 15 single- (SBPCFC)
and 41 DBPCFCs were undertaken in these patients to
secure the diagnosis.
Final confirmation of the diagnosis GMA was obtained
by performance of the gold standard for food allergy
diagnostics (given below) [1-4,12]. 15 single- (SBPCFC)
and 41 DBPCFCs were undertaken in these patients to
secure the diagnosis.
Their clinical symptoms, signs of atopy, type of allergic
reactions involved and the main causative food allergens
detected during BPCFC are summarized in Tables 1 and
2 for the whole group. Table 3 shows all individual reac-
tions of each allergy patient related to serum IgE, atopy
status and the allergy type involved.
Confirmation of the diagnosis gastrointestinally mediated
allergy (GMA) by oral food challenge tests
Blinded placebo-controlled food challenge tests (BPCFC)
were done after extensive exclusion of various otherdifferential diagnoses as indicated above. At least two
weeks in advance of BPCFC, any antiallergic, immuno-
suppressive or steroid treatment had been discontinued
for all patients and patients underwent a hypoallergenic
diet at least 3 days before food challenges. Food chal-
lenges were only performed when patients had a clear
resolution of their symptoms under the hypoallergenic
diet with symptom scores < 3 points (Table 4). GMA was
finally confirmed in each patient by blinded, placebo-
controlled food challenge tests (BPCFC) adding the
putative allergen to a basic diet containing rice, potato, oli-
gopeptides (Survimed OPD, Fresenius, Germany) and tea.
Allergens were freshly prepared and given to the patients
via a nasogastric tube as described previously [4,11,12].
SBPCFC- and DBPCFC were performed in a standardised
fashion, while patients were hospitalised and symptoms
have resolved during hypoallergenic diet (score < 3 points).
Food antigen was administered in three different doses
over one test day. Initially, a 1/20 dilution of the native al-
lergen solution was slowly administered via a pump at the
nasogastric tube (volume up to 100ml for 1 hour), followed
Table 2 Allergy types according to Coombs and Gell, clinical reactions provoked by blinded, placebo-controlled food
challenge tests (BPCFC) and causative allergens in the study group with gastrointestinally mediated allergy (GMA)
Allergy type Clinical reactions during food challenge Eliciting allergens
n = patients n = patients
Type I allergy
(Systemic IgE)
25 patients 10 diarrhoea 7 nuts
18 atopics (72%) median serum IgE 4 pruritus, vomiting, abdominal pain, tachycardia 6 egg, wheat
5 milk
4 hazelnut, soy flour
3 pollen associated fruits
2 rye, celery, spice
1 fish, maize, oat, barely, rice, peach,
carrot, banana, pork
198 (84.5 – 405) 4 epigastric pain, bloating
2 nausea, hypotension, GI- bleeding
1 dyspepsia, flatulence, arthralgia, restlessness,
fever, urticaria, abdominal colics,
Type I allergy 12 diarrhoea 8 milk
(Local IgE) 10 abdominal pain 5 nuts, pork, egg, wheat
n = 22 5 bloating 3 rice, pollen associated fruits
11 atopics (50%) 4 colitis 2 soy flour, maize, celery
Median serum IgE 3 GI-bleeding 1 fish (salmon), beef, rye,
39 (23 – 77.5) 2 pruritus, eosinophilia, urticaria hazelnut, moulds
1 hypotension, dysphagia tachycardia,
gastroesophageal reflux, ascites, edema
Type III allergy (serum immune complexes) 3 diarrhoea 4 soy flour
2 bloating, abdominal pain 2 pork
1 GI-bleeding, tachycardia, hypotension, nausea 1 rye, ricen = 4
2 atopics (50%)
median serum IgE
38.5 (20 – 83)
Type IV allergy 6 diarrhoea 5 rye
(Cellular hypersensitivity) 3 abdominal pain, pruritus 3 wheat, beef
n = 12 2 bloating, vomiting, flatulence, hypotension 2 milk, pork, soy flour, egg, soy bean
5 atopics (41.6%)
Median serum IgE
31 (10 – 57.5) 1 tachycardia, flush, GI-bleeding 1 nuts, chicken, maize, moulds,
pollen-associated fruits
N = patient number, OAS oral allergy syndrome.
Atopy status was defined as positive, when history or clinical manifestation of the patient gave evidence for seborrheic dermatitis, atopic dermatitis or eczema,
asthma bronchiale and/or allergic rhino - conjunctivitis.
For definition of the allergy type, the most dominant immunological signs were chosen to classify the ongoing allergic mechanisms in this population of patients
with manifest gastrointestinally mediated allergy. However, some patients displayed symptoms that suggested more than one definitive type of allergy. Type I
allergy (systemic IgE sensitization) was recognised when positive skin and/or antigen specific IgE levels were present in serum (>0.35 U/ml), type I allergy (local
IgE sensitization) was diagnosed when intestinal lavage fluid contained elevated food antigen-specific levels of IgE (>0.35 U/mg protein) [11,23].
Type III allergy was found in 4 patients who showed formation of either IgA, IgM and/or IgE immune complexes during or after allergen application by blinded
food challenge, while pre-challenge serum immune complexes were normal during potato-rice diet.
Type IV allergy was diagnosed or suspected in 7 patients and 5 with mixed allergy types who showed markedly increased production of serum TNF levels during
or after food challenge, while pre-challenge TNF levels were normal during potato-rice diet. Additionally, in one patient type IV allergy was considered because of
a positive antigen-specific lymphocyte proliferation test corresponding to the results of BPCFC.
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and finally, a dose of the full strength native allergen solu-
tion was provided with a volume of 200ml with fluidallergens or 0.6g/kg body weight of solid, but homogenized
allergens, respectively, for 3 hours [11,12]. One single food
antigen was tested per day. Food challenges were stopped
Table 3 List of individual symptoms, causative allergens, serum IgE and identified allergy types in each patient of the
study group with gastrointestinally mediated allergy (GMA)
Pat. no. Main symptoms & allergen(ssensitivity) Atopy status & serum-IgE Type of allergy
1 Diarrhoea, flush, pruritus - 76 Type I (systemic IgE)
Soy flour, egg
2 Abdominal pain, loose stools + 210 Type I (systemic IgE)
Bloating
Wheat, nuts
3 Vomiting, diarrhoea + 112 Type I (systemic IgE)
Egg, wheat, soy
4 Abdominal pain, urticaria - 21 Type I (local IgE)
Fish (salmon)
5 Diarrhoea, abdominal pain + 65 Type I (systemic IgE)
Dyspepsia, vomiting
Hazelnut, tree pollens
6 Diarrhoea - 89 Type I (systemic IgE)
Wheat, maize, barley
7 Vomiting, loose stools + 112 Type I (systemic IgE)
Right lower quadrant pain
Rice, peach
8 Profuse watery diarrhoea - 398 Type I (systemic IgE)
Milk, soy, fish
9 Diarrhoea, bloating, tachy- + 34 Type III (immune com-
Cardia Plexes present) or
Pork, beef, soy Type IV (?)
10 Pruritus, Rhinitis, tachycardia - 54 Type I (systemic IgE)
Bloating, diarrhoea
Nuts, milk
11 Colitis, diarrhoea, arthralgia - 66 Type I (systemic IgE)
Oral allergy syndrome, rhinitis
Celery, carrot, tree & grass pollen
12 Bloody diarrhoea, hypotension, - 6 Type I (local IgE)
And/or abdominal pain, bloating Type III (IMMUNE
rice, soy Complexes)
13 Fever, diarrhoea, hypotension + 722 Type I (systemic IgE)
Nuts
14 Diarrhoea, vomiting, abdominal - 6 Type IV (cellular hyper-
Pain Sensitivity
cereals (rye, wheat)
15 Bloating, diarrhoea, eosinophilia + 130 Type I (systemic Ige)
Milk, egg
16 Atopic eczema, diarrhoea, colitis + 76 Type I (local IgE)
Abdominal pain Type IV (cellular hyper-
Nuts, tree pollen Sensitivity ?)
17 Rhinitis, vomiting, diarrhoea + 111 Type I (local IgE)
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Table 3 List of individual symptoms, causative allergens, serum IgE and identified allergy types in each patient of the
study group with gastrointestinally mediated allergy (GMA) (Continued)
Nuts, egg
18 Diarrhoea, bloating + 28 Type I (local IgE)
Wheat, milk
19 Eosinophilia, bloating, diarrhoea + 289 Type I (systemic IgE)
Egg
20 Gastrointestinal bleeding, colitis + 80 Type I (systemic IgE)
Wheat, hazelnut
21 Chronic diarrhea, bloating, pain - 12 Type IV
Pork, beef
22 Weight loss, diarrhea, pain - 43 Type III (immune
soy Complexes)
23 Loose stools, abdominal pain + 78 Type I (local IgE)
Rice, egg
24 Diarrhea, anaphylaxis + 312 Type I (systemic IgE)
Milk, egg
25 Weight loss, malabsorption - 34 Type I (local IgE)
Milk, pork, wheat
26 Tachycardia, abdominal pain - 7 Type I (local IgE)
Pork
27 Colitis, abdominal pain, pruritus + 92 Type I (local IgE)
nuts, apple, tree pollen
28 Chronic diarrhea - 8 Type IV
Rye,
29 Gastroesophageal reflux + 28 Type I (local IgE)
Eosinophilia, intermittent diarrhea
milk, beef, tree pollen
30 Anaphylaxis, urticaria + 467 Type I (systemic IgE)
Abdominal colics
Egg, milk
31 Diarrhoea, bloating + 28 Type I (local IgE)
Wheat, milk
32 Microscopic colitis, flush - 32 Type IV
Pruritus
Maize, rye
33 Chronic diarrhea, bloating + 77 Type I (local IgE)
Abdominal pain, rhinitis
Milk, house dust mite, grass pollen
34 Epigastric and abdominal pain + 420 Type I (systemic Ige)
Tachycardia, rhinitis, asthma bronchiale
Nuts, wheat, rye, oat
35 Microscopic enteritis and colitis - 22 Type I (local IgE)
Malabsorption, pruritus
Egg, wheat, pork
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study group with gastrointestinally mediated allergy (GMA) (Continued)
36 Eosinophilic enteritis, ascites - 71 Type I (local IgE)
Abdominal pain, loose stools
Maize, rice, fruits
37 Allergic rhinoconjunctivitis, + 412 Type I (systemic IgE)
Epigastric pain, pruritus
Pollen, spice, celery
38 Chronic diarrhea, nausea + 123 Type I (systemic IgE)
Soy, pork, rye, pollen and type III (immune complexes)
39 Eosinophilic esophagitis + 24 Type I (local IgE) and
Atopic dermatitis Type IV
Egg, milk, pollen
40 Vomiting, flatulence, - 8 Type IV
Hypotonia
Wheat, rye, soy bean, milk
41 Gastric & duodenal ulcer - 91 Type I (local IgE)
Gastrointestinal bleeding
Eosinophilia
Soy flour, nuts, celery
42 Weight loss, malabsorption + 217 Type I (systemic IgE)
Allergic rhinoconjunctivitis
Apple, nuts, latex
43 Intermittent diarrhea - 370 Type I (systemic IgE)
Hazelnut
44 Tachycardia, restlessness - 28 Type I (systemic IgE)
Loose stools
Wheat, pollen
45 Oral allergy syndrome, + 198 Type I (systemic IgE)
Epigastric pain
Nuts, fruits, pollen
46 Watery diarrhea - 36 Type I (local IgE)
Egg, milk
47 Chronic diarrhea, flatulence - 30 Type IV
soy bean, beef, chicken
48 Urticaria, oral allergy syndrome + 42 Type I (local IgE)
Colitis
Nuts, pollen
49 Atopic eczema, proctitis + 732 Type I (systemic IgE)
Spice, pollen, hazelnut
50 Gastrointestinal bleeding + 74 Type I (local IgE) and
From enterocolitis Type IV
Rye
51 Dysphagia, epigastric pain - 141 Type I (local IgE)
Oral allergy syndrome
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Table 3 List of individual symptoms, causative allergens, serum IgE and identified allergy types in each patient of the
study group with gastrointestinally mediated allergy (GMA) (Continued)
Fruits, hazelnut, celery
52 Chronic diarrhea, abdominal - 65 Type I (local IgE)
pain and edema
pork, maize, moulds
53 Lymphocytic colitis + 122 Type I (systemic IgE)
Pruritus, hypotonia and type IV
Banana, fruits
54 Nausea, vomiting, flatulence + 780 Type I (systemic IgE)
Nuts
55 Oral allergy syndrome, chronic - 96 Type I (local IgE)
Diarrhea
Wheat, rye
56 Pruritus, weight loss, - 41 Type IV
Malabsorption
Wheat, rye, soy flour
Atopy status was defined as positive, when history or clinical manifestation of the patient gave evidence for seborrheic dermatitis, atopic dermatitis or eczema,
asthma bronchiale and/or allergic rhino - conjunctivitis.
For definition of the allergy type, the most dominant immunological signs were chosen to classify the ongoing allergic mechanisms in this population of patients
with manifest gastrointestinally mediated allergy. However, some patients displayed symptoms that suggested more than one definitive type of allergy (see for
example patient No. 9, 12, 16 etc.): Type I allergy (systemic IgE) was recognised when positive skin and/or antigen specific IgE levels were present in serum, type I
allergy (local IgE) was diagnosed when intestinal lavage fluid contained elevated food antigen-specific levels of IgE (>0.35 U/mg protein) [11,23].
Type III allergy was found in 4 patients (no. 9, 12, 22, 38) who showed formation of either IgA, IgM and/or IgE immune complexes during or after allergen
application by blinded food challenge, while pre-challenge serum immune complexes were normal during potato-rice diet.
Type IV allergy was diagnosed or suspected in 8 patients who showed markedly increased production of serum TNF levels during or after food challenge,
while pre-challenge TNF levels were normal during potato-rice diet. Additionally, in one patient (no. 14) type IV allergy was considered because of a positive
antigen-specific lymphocyte proliferation test.
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symptom score of greater 6 points (Table 4), while reaction
scores between 3 – 6 points were judged equivocal requir-
ing re-challenge at another randomised provocation day
[11,12]. When significant or equivocal reactions occurred,
masked oligo-peptide diet as placebo was given the next
day. Placebo consisted of an oligopeptide-diet (protein
source: hydrolysed soybean, Survimed OPD, Germany),
which was also used for base-line nutrition (minimum:
1800 kcal/day), in conjunction with a potato-rice diet in
order to prevent a catabolic state [11-13]. A single blind
challenge was performed in 15 patients (26.7%, patients
unaware of provocation protocol), while a double-blind
challenge was carried out in 41 patients (73.2%, patients
and physicians unaware of the provocation protocol)
[8,11,12]. Blinding of the food antigens was managed by
nutritionists, who were responsible for the preparation and
addition of the allergens to usually tolerated foodstuff or to
the oligopeptide solution, respectively [4,11,12].
Physicians selected the type of food to be tested either
on the basis of the patients’ history, skin prick tests and
serum or intestinal antigen-specific IgE tests or from the
list of given staple foods. During the provocation pro-
cedure, the patients were provided with a peripheralvenous line, and all medical staff involved was trained
for medical intervention in case of an anaphylactic reac-
tion. For the definition of all food allergic reactions, a
modified scoring system (Table 4) was applied [11,12].
Main symptoms of patients evoked by the food allergen
challenges are listed in Table 2 for the whole group and
in Table 3 for each patient individually.
During BPCFC, at least one reproduction of an aller-
gen induced clinical reaction and one or two placebo
challenges were included for every patient. In total, after
several provocation periods 1 – 9 food allergens (median
4, 1 – 14) have been tested per patient by BCFC with a
cumulative median of 12 test days (3 – 28 days).Definition of allergy types
Food hypersensitivity was diagnosed as IgE-mediated
GMA only when food-specific immune events were de-
tected through positive skin tests (mean wheal diameter
equal to the histamine reaction or > 3 mm in diameter
[1,9,11-13]), serum antigen-specific IgE > 0.35 KU/L or
greater (level 1 on the specific IgE scale, Phadia Cap-
system, Phadia, Uppsala, Sweden) or through proof of
intestinal IgE > 0.35KU/mg protein by endoscopically
Table 4 Erlangen symptom score used to quantify unrestricted diet, hypoallergenic diet and reactions during blinded,
placebo-controlled food challenges (BPCFC)
I. General symptoms
1. Reduction of general condition 2. Core temperature
Mild 1 Subfebrile; 37,5 to 38,0°C 1
Moderate 2 Low fever; 38,0 to 39,0°C 2
Severe 3 High fever; >39,0°C 3
Intolerable 4
II. Organotropic symptoms
1. Eyes 2. CNS
- Itching/burning - Conjunctiva - Headache/vertigo - Sensitivity
Mild 1 Erythema 1 Mild 1 Paresthesia 1
Moderate 2 Swelling unilateral 2 Severe 2 Prickling 1
Continuous 3 Swelling bilateral 3 Migraine 3 Heat (feeling) 1
3. Cardiovascular system
Decrease of blood pressure (systolic) Increase of heart rate
>10 mm hg 3 >10/min 3
>20 mm hg 6 >20/min 6
>30 mm hg 10 >30/min 10
4. Respiratory systems
- Nasal congestion - Prickling/itching (nose & pharynx)
Unilateral 1 Occasional 1
Bilateral 2 With rubbing 2
Mouth breathing 3 Continuous 3
- Rhinorrhea - Sneezing
Occasional 1 Occasional 1
Frequently 2 Frequently 2
Continuous 3 Continuous 3
- Larynx - Pulmonary function test
Hoarseness 2 FEV1 80–60% / PEF <75% (baseline) 2
Laryngeal edema 5 FEV1 < 60% / PEF < 50% (baseline) 5
- Bronchial obstruction (auscultatory) - Cough
Expiratory wheezing 2 Occasional 1
In- & expiratory wheezing 5 Frequently 2
Massive obstruction (silent lung) 10 Staccato cough 3
5. Gastrointestinal tract
- Buccal cavity - Abdomianl pain/cramps
Erythema/thumbness 1 Mild 1
Swelling 2 Moderate 2
Aphts 3 Severe 3
- Esophagus - Diarrhea
Pain 1 Loose Number of stools x 1
Dysphagia/pyrosis 2 Liquid Number of stools x 2
Bolus (feeling) 3 Bloody Number of stools x 3
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Table 4 Erlangen symptom score used to quantify unrestricted diet, hypoallergenic diet and reactions during blinded,




Vomiting Episodes x 2
6. Locomotor apparatus
- Arthralgia (including spinal column) - Arthritis (with joint effusion)
1 joint 1 1 joint 1
2–4 joints 2 2–4 joints 2
>4 joints 3 >4 joints 3
7. Skin
- Pruritus -Erythema
Occasional 1 Mild 2
>2 minutes 2 Moderate, <50% body surface 5




Generalized, generalized flush 10
Result:
<3 points Negative result
3–5 points Questionable result
>6 points Positive result
Individual reactions and symptoms during the test days with unrestricted diet, potato-rice diet and during the food challenge tests were documented each for a
24 hours period and calculated for the corresponding diet and day, respectively.
Food challenges were only performed when patients had a clear resolution of their symptoms under the hypoallergenic diet with symptom scores < 3 points.
Symptom scores higher than 6 points were judged as positive reactions and compared with the score during potato-rice diet [11,12].
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challenge score > 6 points [11-13].
Food hypersensitivity was diagnosed as non-IgE-
mediated GMA when 1) a reproducible clinical adverse
reaction to the food antigen(s) occurred after allergen
application (up to 24–48 hours) without evidence of
cutaneous, systemic or local IgE sensitization, but 2)
food-specific immune phenomena could be demonstrated
during or after provocation (e.g. eosinophilic cationic pro-
tein, tumor necrosis factor, immune complexes etc.,
Table 1 [1,3,7-9,12]) and 3) other intolerance mechanisms
have been excluded (histamine intolerance, salicylate sen-
sitivity etc.).
Control group
The control group of 44 individuals consisted of 19
healthy food-tolerating volunteers (43.1%) and 25 pa-
tients (56.8%) with non-allergic carbohydrate malassimi-
lation (n = 20), exocrine pancreatic insufficiency (n = 3)
and psychosomatic disease (n = 2).
All controls were also immunologically tested by skin
prick tests for environmental allergens (moulds, fibres,bacteria, pollen, dust) and staple food allergens (beef,
egg, fish, fruit, pork, wheat, rye, soy, bran, milk, cheese
and nuts).
While 7 of the 19 food-tolerating volunteers had a his-
tory for extraintestinal allergy (rhinitis due to pollen and/or
house dust mite sensitization), these 19 patients had non-
food related symptoms. Among the 25 patients adverse re-
actions to various foods, above mentioned differential diag-
nostic steps including detection of food-specific IgE against
staple foods and endoscopic-histological examination of
the upper and lower gastrointestinal tract revealed carbo-
hydrate malassimilation in 20 patients (45.4% of control
group; lactose, fructose, and/or sorbitol malabsorption with
clinical remission to diet), exocrine pancreatic insufficiency
in 3 patients and psychosomatic disorders in 2 patients,
but no other inflammatory, neoplastic, allergic or immuno-
logical disorder. However, 6 of these 20 malabsorptive pa-
tients underwent DBPCFC due to suspected non-IgE-
mediated allergy, but no clinical reactions were recorded.
Thus, these individuals were also classified as non-allergic
controls with symptomatic carbohydrate malassimilation
or pancreatic insufficiency. The clinical characteristics,
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tions of the control group are listed in Table 1.
Urinary mediator excretion test during unrestricted diet
and hypoallergenic diet
To evaluate urinary mediator excretion of histamine and
methylhistamine patients with GMA (study group) and
all persons of the control group underwent the following
functional diet test: All individuals ingested during two
subsequent days an unrestricted diet (day 1 and 2),
followed by two further days with potato-rice diet (day 3
and 4). This functional diet test was performed before
BPCFC with standardised food antigens to identify pa-
tients with enhanced histamine production.
The unrestricted diet was explained twice to the pa-
tients and controls, and it included ingestion of all listed
staple foods (as given for skin prick testing and food-
specific IgE), at least once, either at day 1 and/or day 2.
The staple foods encompassed all common food groups
of German nutrition habits. Among these staple foods
following qualitative groups were allowed along with
sugar and salt: Beef, egg, fish, fruit, pork, wheat, rye, soy,
bran, milk, cheese, nuts, barley, coffee, oats, maize,
apple, peach, banana and vegetables, but quantitative
amounts were not recorded for practical reasons. Extra-
ordinary food allergens like kiwi, Asiatic spices, curry,
sesame etc. were not allowed as well as alcoholic bever-
ages. During all test days symptoms were recorded, doc-
umented in a score and thus, patients improving in
symptoms during potato-rice diet could be identified.
12-hour urinary mediator excretion was measured from
each test day from an overnight collection period 6.00
p.m. to 6.00 a.m. [12,13].
During unrestricted diet patients ate the given staple
foods and even their suspected foodstuffs until 2.00 p.m.
and are allowed to drink 1.5 – 2.0 l water per test day. No
immunosuppressive drugs, antiallergic medication nor
consumption of alcohol was allowed during the urine
collection days. After 2.00 p.m. patients were not allowed
to ingest any foods up to the next morning to avoid food-
induced urinary histamine contamination, and to
adequately monitor endogenously produced histamine
amounts during the 12-hour overnight collection
period [12-15]. In the case of suspected severe allergic
symptoms (anaphylaxis, hypotension, asthma, gastro-
intestinal bleeding etc.) this functional urinary mediator
test was conducted on the ward or intensive care unit, re-
spectively, with corresponding circulation monitoring.
During hypoallergenic potato-rice diet patients were
allowed to eat only potato and rice, with or without salt
and/or sugar until 2 p.m. and to drink 1.5 – 2.0 l water
per test day. After 2.00 p.m. patients were not allowed to
further ingest potatoes or rice. Urine collection period
was also from 6 p.m. to 6 a.m. In three cases of riceallergy, the hypoallergenic diet was reduced to intake of
potato only.
Urine from test day 1 and 2 (normal diet, all foodstuffs)
as well as from test day 3 and 4 (potato-rice diet) was each
prepared with 1 N HCL after the first urine portion to
avoid bacterial contamination and all samples were proc-
essed as previously described [12,15,16]. Only urine sam-
ples with pH < 3 were taken for further analysis.
Histamine and methylhistamine measurement from urine
Urinary histamine (UH) was measured in 12-hour urine
samples by an ELISA according to manufacturers’ instruc-
tions (IBL Immunobiological Laboratories, Hamburg,
Germany; sensitivity histamine 1.3 ng/ml) [17].
Urinary methylhistamine (UMH) was measured by tan-
dem mass spectrometry (Medical Laboratory Buchwald/
Schultis, Weiden, Germany). For tandem mass spectrom-
etry 1 ml urine samples were neutralised and checked
for pH, and purified after addition of an internal standard
(1 – methylhistamine D3, Dr, Ehrensdorfer GmbH,
Augsburg, Germany) by ion exchange (cation exchange
Amberlite CG50, Sigma, Munich, Germany). After separ-
ation from matrix constituents urine eluates were then
quantitatively analysed by tandem mass spectrometry
(Ionics with HSID interface, Ionics MSV, Almere,
Netherlands) using multiple reaction monitoring mode
with the ion pairs 126.1/109.2 and 129.1/112.2, respect-
ively, as internals standards [18].
The sensitivity of tandem mass spectroscopy was
2.6 ng/ml, test linearity was usually achieved between
7.8 – 2000 ng/ml with recovery of 97.7%.
As the rates of mediator excretion may be influenced
by renal function, weight and body size, values were re-
lated to creatinine excretion. Concentrations of UH and
UMH were expressed as μg/mmol creatinine x m2 body
surface area (BSA) [12,15].
Statistics
Statistical analysis was done by GraphPadPrims Soft-
ware, using descriptive statistics with median and 25 –
75% interquartile range. Mean + 1 SD of controls was
used to calculate the normal range of mediator excretion
and correlations were done by Spearmann coefficient.
Significant differences were calculated by Wilcoxon
matched pairs test when comparing both diets within
one group. For comparisons between the groups GMA
and controls the Mann–Whitney test (U-test, unpaired)
was used.
Ethics approval and funding source
All patients and controls gave their informed consent
and the study protocol was approved by the local ethics
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n = 56 patients
control group
n = 44 individuals 
Figure 4 Urinary methylhistamine excretion (UMH) in patients
with gastrointestinally mediated allergy (GMA) and controls.
Horizontal lines represent the median of the group. Comparison of
mediator excretion in both groups during unrestricted diet and a
hypoallergenic elimination diet.Results
Characteristics of mediator test analysis and individual
mediator excretion
Coefficients of intra- and interassay variation of 211
urine samples for detection of methylhistamine by tan-
dem mass spectroscopy were 3.2 and 4.1%, respectively.
The determination of H by ELISA showed an intra- and
interassay variation of 4.1 and 9.8% respectively.
Intraindividual variation of UH and UMH of controls
during both days with unrestricted diet was 21.2 + 14%
and 17.6 + 8.1%, respectively. In the GMA group,
intraindividual UH excretion showed a markedly higher
coefficient of variation (39.1 + 17.9) than UMH (19.7 +
11.0%) during unrestricted diet at day 1 and 2.
As urine samples with pH > 3 might indicate bacterial
contamination, 3/112 samples in the GMA group (2.7%)
obtained from potato-rice diet could not be used for fur-
ther analysis. Urine samples of all other groups and diet
types had normal pH values below 3 and were further
analysed.Control group
When testing for normal distribution of mediator excre-
tion rates, only UH and UMH values of controls during
unrestricted diet and UMH during potato-rice diet
showed a Gaussian distribution, thus median and 25 –
75% interquartile range were given in the Figures 2 and
3 and non-parametric statistical tests were used.
The median rates of UH and UMH excretion from
controls are shown in Figures 3 and 4. In the control






















































n = 44 individuals
gastrointestinally mediated
food allergy (GMA)
n = 56 patients 
Figure 3 Urinary histamine excretion (UH) in patients with
gastrointestinally mediated allergy (GMA) and controls.
Horizontal lines represent the median of the group. Comparison of
mediator excretion in both groups during unrestricted diet and a
hypoallergenic elimination diet.diet forms for UH, while UMH fell significantly during
potato-rice diet in controls (p = 0.008).
When analysing the distribution of individual UH
excretion of controls during unrestricted diet (Figure 5,
Tables 5 and 6), 13 of 88 urine samples (14.7%) showed
UH levels greater than the mean + 1SD (0.99 + 0.68 =
1.67), while 75 urine samples (85.2%) were below this
limit.
When analysing the distribution of individual UMH
excretion of controls during unrestricted diet (Figure 6,
Tables 5 and 6), 12 of 88 urine samples (13.6%) showed
UMH levels greater than the mean + 1 SD (4.4 + 1.8 =
6.2), while 76 urine samples (86.4%) were below this
limit.
The median symptom score of control patients did not
differ between unrestricted diet (1.8; 0 – 4.1) and potato-
rice diet (2.1; 0 – 5.9).gastrointestinally mediated
food allergy (GMA)
n=112 urine samples 
control group












Figure 5 Distribution of individual urine histamine (UH) values
during unrestricted diet in 56 patients with gastrointestinally
mediated allergy (GMA) and 44 controls. The grey box represents
normal values of UH (mean ± 1 SD of controls).
Table 5 Sensitivity, specificity, positive and negative
predictive values for the detection of urinary histamine
(UH) or urinary N - methylhistamine (UMH) as non-invasive
markers of gastrointestinally mediated allergy (GMA)
Urinary histamine (UH) [μg/mmol







*The significance level of 1.67 μg/mmol creatinine x m2 BSA was calculated
from the mean + 1SD of controls during unrestricted diet. Using this criterion
UH was found to reach following test characteristics:
UH sensitivity 50/112 = 44.6%; specificity 75/88 = 85.2%; positive predictive
value 50/63 = 79.3%, negative predictive value 75/137 = 54.7%.
gastrointestinally mediated
food allergy (GMA)
n=112 urine samples 
control group











Figure 6 Distribution of individual urine methylhistamine
(UMH) values during unrestricted diet in 56 patients with
gastrointestinally mediated allergy (GMA) and 44 controls.
The grey box represents normal values for UMH (mean ± 1 SD of
controls).
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Clinical findings in GMA
All 56 proven food allergic individuals (100%) reported
abdominal symptoms, nausea, pain, vomiting and/or
diarrhoea (98%) after certain meals, while postprandial
extraintestinal signs of allergy such as skin reactions,
asthma bronchiale, pruritus and allergic rhinoconjuncti-
vitis occurred only in a small percentage of patients
(39%, Table 2).
Among the 56 allergy patients 29 individuals (57.1%)
had a comorbid pathological H2 breath tests for either
lactose, fructose and/or sorbitol (Table 1).
Urinary mediator results in GMA
The median rates of UH excretion are given in Figure 3
for the whole GMA group. There was no significant
difference in UH between both diet forms in GMA
patients.
But UH was each significantly elevated in GMA pa-
tients during unrestricted diet (p < 0.0001) and potato-
rice diet (p = 0.02) compared to the corresponding diet
in controls.
Among GMA patients 50 of 112 urine samples
(44.6%) had UH levels of greater than the mean + 1SD ofTable 6 Sensitivity, specificity, positive and negative
predictive values for the detection of urinary histamine
(UH) or urinary N - methylhistamine (UMH) as non-invasive
markers of gastrointestinally mediated allergy (GMA)
Urinary methylhistamine
(UMH) [μg/mmol







*The significance level of 6.2 μg/mmol creatinine x m2 BSA was calculated
from the mean. + 1SD of controls during unrestricted diet. Using this criterion
UMH was found to reach following test characteristics:
UMH sensitivity 70/112 = 62.5%; specificity 76/88 = 86.4%; positive predictive
value 70/82 = 85.4%, negative predictive value 76/118 = 64.4%.controls (>1.67), while 62 were below this limit. Sensitiv-
ity, specificity, positive and negative predictive value of
UH are given in Tables 5 and 6.
The median rates of UMH excretion are given in
Figure 4 for the whole GMA group, with significant dif-
ferences among GMA patients ingesting an unrestricted
diet versus a hypoallergenic elimination diet (p = 0.004).
The differences in UMH between GMA and controls were
highly significant when comparing both groups under un-
restricted diet or hypoallergenic diet (each p < 0.0001).
Among GMA patients 70 of 112 urine samples (62.5%)
had UMH levels of greater than the mean + 1 SD of con-
trols (>6.2), while 42 were below this limit. Sensitivity, spe-
cificity, positive and negative predictive value of UMH are
given in Tables 5 and 6.
The median symptom score of GMA patients showed a
significant difference between unrestricted diet (4.4; 3 – 6)
and potato-rice diet (3.0; 1 – 4, p = 0.03) as well as to con-
trols for unrestricted diet (p = 0.02). However, there was
no significant correlation between symptom score and
UH or UMH excretion in GMA (r2 = 0.07, p = 0.6 and
r2 = 0.08, p = 0.7, respectively).
Analysis of urinary mediator excretion rates according to
IgE- and non-IgE induced types in GMA
When analysing all obtained individual UH and UMH
values as shown in Figures 5 and 6 according to the
presence of IgE- and non-IgE induced allergy types
(Tables 2, 3 and 7) UH was each significantly elevated
(p < 0.001) in the IgE- and non-IgE group compared to
controls during unrestricted diet, but not during the
hypoallergenic potato-rice diet (Table 7). There was no
statistical significance between both diet types in the
IgE- and non-IgE induced GMA groups for UH.
Table 7 Urinary histamine (UH) and methylhistamine (UMH) excretion in relation to IgE- and non-IgE induced types of
gastrointestinally mediated allergy (GMA) compared to the control group
UH excretion Unrestricted diet Hypoallergenic potato-rice diet Statistical significance vs control group
unrestricted/hypoallergenic diet
IgE GMA 1.5 (0.9–2.6) 1.1 (0.8–2.2) P < 0.0001/n.s.
Non-IgE GMA 1.4 (1.0–3.2) 1.46 (0.7–1.9) P < 0.0001/n.s.
Control group 0.9 (0.4–1.3) 1.1 (0.6–1.6)
UMH excretion
IgE GMA 7.1 (5.9–11.2) 5.8 (3.9–9.7) P < 0.0001/p < 0.0001
Non-IgE GMA 8.0 (4.8–11.3) 5.5 (3.1–8.2) P = 0.003/p = 0.002
Control group 4.6 (3.2–5.8) 3.8 (2.3–5.1)
UH and UMH excretion rates (median, 25–75th percentile; μg/mmol creatinine x m2 BSA) were separately analysed for the IgE- and non-IgE induced types of GMA.
Statistical significance between GMA groups and controls is given in the table.
In addition, there were no statistical significances for UH in the IgE- and non-IgE GMA group when comparing unrestricted diet versus hypoallergenic diet types
(p = 0.09 and p = 0.27), while UMH in the IgE- and non-IgE GMA group revealed statistical significances (p = 0.04 and p = 0.002) between both diet types.
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and significantly increased in both allergy types (IgE-
and non-IgE group) during the unrestricted diet and the
potato-rice diet compared to controls (Table 7). Interest-
ingly, UMH was also significantly different within the
IgE- or non-IgE GMA group when switching from the
unrestricted diet to the hypoallergenic diet (p = 0.04 and
p = 0.002, respectively).
Discussion
Gastrointestinal complaints after ingestion of various
foodstuffs may result from a great spectrum of patho-
physiological mechanisms, including infectious, toxic,
immunological and non-immunological mechanisms as
well as psychogenic reactions. However, at clinical pres-
entation patients’ history and symptoms may be unspe-
cific, atopy status may be inconsistent, sensitivity and
specificity of antigen-specific IgE and skin tests vary in
different patient subpopulations and the exact aetiology
of food related symptoms often remains unclear [3,7-9].
Thus, the diagnosis of GMA requires a substantial de-
gree of clinical suspicion, especially when patients
present with recurrent postprandial abdominal symp-
toms and characteristic extraintestinal signs of allergic
disease are not clearly observed. For this reason, the deter-
mination of biochemical mediator abnormalities resulting
from degranulating allergic effector cells (e.g. basophils,
mast cells) may facilitate the diagnosis of gastrointestinal
food allergy. Thus, in an attempt to identify patients with
histamine associated clinical symptoms, the results of a
standardised functional urine mediator test were analysed
in a cohort of patients in whom gastrointestinal food allergy
has been confirmed by systemic and/or local immuno-
logical analysis as well as BPCFCs (Tables 1, 2, 3 and 4).
To imitate the clinical situation of patients with GMA,
UH and UMH were collected first during a normal, un-
restricted diet at two consecutive days (mostly at home,
based on staple foods and putative allergens) which wassuspected of inducing their complaints. Compared to con-
trols who ingested also staple foods during unrestricted
diet at day 1 and 2, patients with GMA exhibited signifi-
cantly more symptoms than normal individuals under an
unrestricted diet, and UH and UMH excretion were found
to be highly significantly increased in allergic individuals.
Although in the past, earlier attempts to diagnose GMA
by histamine mediator excretion failed to show such clear
results [14,19], these highly significant results may be the
result of a strong standardization of this functional medi-
ator test as described above (food ingestion up to 2 p.m.,
urine collection period from 6 p.m. to 6 a.m., each diet
2 days, fluid volume, water only etc. [4,13,15]) and an ap-
propriate diagnostic work up for patient selection (Figure 1).
Since the excretion of histamine, methylhistamine, imid-
azole acetic acid and its conjugates after food intake has
been reported to occur within 1 – 3 hours after meal as a
result from gastric acid stimulation in humans [20], intake
of any foodstuffs within 4 hours before start of the urine
collection period was not allowed in our functional medi-
ator excretion study [4,12,13,15]. Before start of the urine
collection period at 6 p.m. patients were advised to excrete
their urine. Thus, urine samples collected after 6 p.m. and
their mediator values obtained reflect more precisely the
endogenous 12-hour histamine production overnight than
exogenous histamine intake [13-15,20]. In addition, further
standardisation was achieved by expression of all mediator
excretion rates in relation to renal function and body sur-
face area [12-15,21,22]. Finally, the results reported here
arise from a cohort of fully confirmed GMA, since usual al-
lergy tests were refined by search for intestinal IgE and
proven by BPCFCs [4,7,9,11,12,16,21].
After two days of unrestricted diet clinical symptoms
from GMA patients declined significantly, and UMH
levels decreased in parallel and more pronounced than
UH, indicating that the clinical effects of the hypoaller-
genic diet with potato-rice are accompanied at least, in
part, by a lower rate of effector cell degranulation and/or
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tients with IgE-dominated as well as non-IgE dominated
allergy types in adult GMA (Table 7), indicating that even
in non-IgE GMA histamine release events and histamine
production may be substantially involved [2,4-8,12,16,22].
But there was no correlation of UMH values with the clin-
ical symptom score, indicating that several other mediators
than histamine may also influence the symptoms of pa-
tients with gastrointestinal food allergy (e.g. prostaglandin
D2, leukotrienes, platelet activating factor, tryptase etc.
[5-7,12,16,22,23]).
While the elimination diet did not induce a clear de-
crease of UH excretion in allergic individuals and controls,
UMH was found to decrease significantly and similarly in
GMA patients (IgE- and non-IgE type) and controls during
potato-rice diet, but in controls at a considerable lower
UMH level. While GMA patients remained with their
UMH levels mostly above 6.2 μg UMH/mmol creatinine x
m2 BSA, controls were clearly below this differentiation
level of 6.2 μg UMH/mmol creatinine x m2 BSA (Figure 3).
The decline of UMH in controls may further indicate that
the quantity of UMH excretion in humans reflects not only
the rate of allergic effector cell degranulation and/or mast
cell number or activity, respectively, but also several other
intervening factors, like nutrient intake, protein content of
the diet etc., resulting in a different extent of gastric acid
stimulation by endogenous histamine dependent mecha-
nisms [6,12-16,19].
However, UMH excretion was found to be highly signifi-
cantly enhanced in both IgE- and non-IgE type of GMA
patients than in controls under both diet forms, showed
lower rates of intraindividual variation and it has been re-
ported to reflect more precisely alterations of the histamine
metabolism than histamine itself [12-14,21,22]. UMH pre-
sents as a possible indicator of systemic histamine produc-
tion and it was found to increase in urine during early and
late phase allergic asthmatic reactions [12,19,21-23]. The
distribution of individual UMH levels in GMA and con-
trols showed a considerable overlap, but in controls most
patients (86.4%) were found to have UMH excretion rates
lower than 6.2 (mean + 1SD). When using a UMH level of
6.2 as an additional diagnostic criterion to raise the suspi-
cion of GMA or, at least, of an enhanced histamine pro-
duction, respectively, 62.5% of patients showed UMH
levels above this criterion, favouring further specialised al-
lergy testing including an elimination trial and perform-
ance of BPCFCs, or, to consider other histamine related
disease conditions like mastocytosis, myeloproliferative dis-
eases etc. [4,6,16,20,21]. Thus, this standardised functional
urine mediator test may help in future to directly iden-
tify patients with enhanced histamine and methylhista-
mine production and excretion during unrestricted diet,
especially in patients with recurrent postprandial abdom-
inal symptoms of yet unknown aetiology (e.g. chronic orintermittent diarrhoea, colic, pain etc., Table 1) both in pa-
tients with systemic signs of allergy (e.g. atopy, Table 1)
and in conditions where local allergic mechanisms (e.g.
entopy, Table 1) have previously been suggested (subpopu-
lations of irritable bowel syndrome, microscopic colitis,
persistent eosinophilia etc. [1,3,5,7,9,16,22-28]). However,
increased excretion rates of UH and UMH are not specific
for GMA, because several other diseases may be accom-
panied by persistently increased excretion of UMH like
mastocytosis, active Inflammatory Bowel Disease, lymph-
oma, hematologic disorders etc. [6,14-16,19,25-28]. But
compared to these diagnoses with persistently enhanced
excretion of histamine and its metabolites, GMA patients
were found to show a clear nutritive modulation of their
UMH excretion within two consecutive days of elimin-
ation diet. Interestingly, such a dynamic, diet induced
change of UMH excretion may serve in future as a sub-
stantial criterion to identify patients with GMA and to
differentiate such patients from above mentioned dis-
ease conditions with persistently enhanced UMH excre-
tion [14,16].
An important limitation of this study is the fact that the
performance and detailed compliance of the unrestricted
and hypoallergenic diet was not strictly supervised by on-
line diaries and strict controls every day. Thus, dietary
mistakes cannot be fully excluded and some allergy pa-
tients may have reduced the intake of a certain staple
foods when perceiving symptoms or suspecting a food as
allergic trigger. This may lead to a lower UMH production
during unrestricted diet and may have influenced the diag-
nostic accuracy of UMH detection negatively, as we have
shown clearly higher UMH levels during DBPCFC when
freshly prepared allergens were applied solely [29]. But the
aim of this functional mediator study was to explore UH
and UMH excretion in patients with food-related symp-
toms during the typical clinical situation, mostly at home,
when patients experienced their postprandial symptoms.Conclusion
Diagnosis of gastrointestinal food allergy is known to be
difficult and needs a strict differential diagnostics and may
be missed when serological, endoscopic and histological
features are inconspicuous. Determination of UMH as an
easy and non-invasive test was found to objectify whether
histamine is involved in certain clinical symptoms. With a
positive predictive value of 85.4% it may further indicate
the gastroenterologist an underlying GMA. Patients with
elevated excretion of UMH and gastroenterological symp-
toms should therefore further undergo detailed allergolo-
gical testing at blood, skin and gut (local IgE) including
food challenge procedures to avoid a rapid diagnosis of
(idiopathic) irritable bowel disease, functional or psycho-
somatic disease [3,16,21,23,26,27].
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